Shanghai Securities News www.cnstock.com, On October 30 that AIM Vaccine announced that the mRNA Respiratory Syncytial Virus (RSV) vaccine developed by the group's holding subsidiary has recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, marking a new stage in the development of the vaccine.

Currently, there is no approved antiviral specific drug for RSV that can be used clinically worldwide, and prevention of RSV has become an important strategy to counter its health threats. Vaccination for active immunization prevention is an effective means to avoid severe RSV infection. In the WHO pre-qualification list for vaccines, the RSV vaccine is of high priority.

China has not yet approved the RSV vaccine for marketing, and there are RSV vaccines from GlaxoSmithKline and Pfizer on the market worldwide. In 2023, the global sales of RSV vaccines were $2.46 billion. According to industry consultant China Insights Consultancy (CIC)'s forecast, it is expected that by 2030, the global market size of RSV vaccines will reach about $16.7 billion (about 130 billion Hong Kong dollars).

According to AIM Vaccine's announcement, RSV infection is an important cause of death in infants under one year of age and also an important factor in respiratory tract infection deaths among the elderly. At the same time, people who have been infected with RSV still have the possibility of being infected with RSV again.

As one of the earliest enterprises in China to develop mRNA vaccine products and one of the first domestic vaccine enterprises to obtain independent patents for mRNA technology, AIM Vaccine has now opened up the entire lifecycle process of mRNA vaccine R&D and production. After completing clinical trials, it can quickly achieve the industrialization of mRNA vaccine products and accelerate the commercialization process of vaccine products. At the same time, AIM Vaccine has established a comprehensive mRNA vaccine quality management system and a commercial-scale production workshop that meets GMP standards, with strong mRNA technology platform and industrialization capabilities.

The company will accelerate the clinical trials of the mRNA Respiratory Syncytial Virus (RSV) vaccine. As a new blockbuster single-item in the global vaccine market, this product is expected to become a new performance growth point for the company after its launch.